BRILACIDIN
An immunomodulatory drug candidate with anti-inflammatory and antibiotic properties granted Fast Track status
KEVETRIN
Orphan-designated p53-modulating drug candidate in a Phase 2a trial for late-stage ovarian cancer
Innovation Completes Licensing Agreement with Alfasigma
Alfasigma to Develop Brilacidin for UP/UPS in Inflammatory Bowel Disease
FIRST-IN-CLASS DRUG CANDIDATES
With dermatology, oncology, anti-inflammatory, and antibiotic applications
LEVERAGING THE BODY’S NATURAL DEFENSE
Brilacidin—the first in a novel class of immunomodulatory drugs
An immunomodulatory drug candidate with anti-inflammatory and antibiotic properties granted Fast Track status
Orphan-designated p53-modulating drug candidate in a Phase 2a trial for late-stage ovarian cancer